Analysts think MTVA stock price could increase by 990%
Mar 14, 2025, 11:25 AM
0.00%
What does MTVA do
NeuroBo Pharmaceuticals, based in Cambridge, Massachusetts, develops multi-modal therapies, including DA-1241 for MASH and Type 2 Diabetes, and DA-1726 for obesity. The company went public on August 5, 2016.
6 analysts think MTVA stock price will increase by 990.34%. The current median analyst target is $15.81 compared to a current stock price of $1.45. The lowest analysts target is $10.10 and the highest analyst target is $24.15.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.